JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Celsion Corp

Atvērts

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Darbinieki

25

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-9.9M

938K

Iepriekšējā atvēršanas cena

0

Iepriekšējā slēgšanas cena

0

Celsion Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. okt. 23:50 UTC

Karstas akcijas

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025. g. 28. okt. 23:25 UTC

Peļņas

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025. g. 28. okt. 23:18 UTC

Peļņas

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025. g. 28. okt. 22:20 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025. g. 28. okt. 22:13 UTC

Peļņas

Wal-Mart de Mexico Net Profit Falls in 3Q

2025. g. 28. okt. 21:38 UTC

Peļņas

Correction to Visa Sales Jump Article

2025. g. 28. okt. 21:17 UTC

Peļņas

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025. g. 28. okt. 21:07 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- Update

2025. g. 28. okt. 21:02 UTC

Peļņas

Mondelez Tempers Outlook as Costs Rise

2025. g. 28. okt. 23:51 UTC

Tirgus saruna

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025. g. 28. okt. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025. g. 28. okt. 23:02 UTC

Peļņas

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025. g. 28. okt. 23:01 UTC

Peļņas

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025. g. 28. okt. 22:46 UTC

Peļņas

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025. g. 28. okt. 22:45 UTC

Peļņas

SK Hynix 3Q Net KRW12.6T >000660.SE

2025. g. 28. okt. 22:44 UTC

Peļņas

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025. g. 28. okt. 22:43 UTC

Peļņas

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025. g. 28. okt. 22:42 UTC

Peļņas

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025. g. 28. okt. 22:20 UTC

Peļņas

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025. g. 28. okt. 22:02 UTC

Peļņas

Review & Preview: Earnings Extravaganza -- Barrons.com

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025. g. 28. okt. 21:20 UTC

Peļņas

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025. g. 28. okt. 21:19 UTC

Peļņas

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025. g. 28. okt. 21:18 UTC

Peļņas

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Salīdzinājums

Cenas izmaiņa

Celsion Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

$

Par Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
help-icon Live chat